- 72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;
- Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo;
Reported Saturday, Vera Therapeutics Presented 72-week EGFR Stabilization And Rapid Hematuria Improvement In Phase 2b ORIGIN Study Of Atacicept In IgAN At The 61st European Renal Association Congress
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.